Background After breast-conserving surgery, 90% of local recurrences occur within the index quadrant despite the presence of multicentric cancers elsewhere in the breast. Thus, restriction of radiation therapy to the tumour bed during surgery might be adequate for selected patients. We compared targeted intraoperative radiotherapy with the conventional policy of whole breast external beam radiotherapy.
Introduction
During the past 50 years, the conceptual approach to breast cancer treatment has shifted from radical mastectomy 1 to local treatment that preserves the breast and axillary lymph nodes along with adjuvant systemic therapy. Breastconserving surgery followed by post operative whole breast external beam radiotherapy is now the standard of care for suitable patients with early breast cancer.
External beam radiotherapy is a safe and eff ective treatment; the risk of side-eff ects is low, but since breast cancer is common, the absolute number of women with complications and side-eff ects is large. More importantly, the 3-7 weeks of a typical postoperative radiotherapy schedule is at best inconvenient for working women or exhausting and often untenable for elderly women. Although many studies [2] [3] [4] have failed to identify a subgroup of patients in whom radiotherapy can be completely avoided, whether irradiation of the whole breast is necessary in all or a subgroup of patients remains unclear.
Many observational studies and randomised clinical trials have shown that more than 90% of recurrent disease occurring in the breast is within the index quadrant, [5] [6] [7] [8] [9] [10] [11] [12] [13] which is by contrast with the fi ndings of three-dimensional analysis of mastectomy specimens that show that 63% of breasts harbour occult cancer foci, with 80% of these situated remote from the index quadrant. [14] [15] [16] These widespread and occult multifocal or multicentric cancers in other quadrants of the breast therefore appear to remain dormant for many years or even decades, and have a low risk of causing clinical tumours. Thus, irradiation of the immediate vicinity of the primary tumour might be adequate for achieving local control of cancer. [14] [15] [16] The TARGIT-A trial was designed to test the hypothesis that in selected patients, substituting the policy of whole breast radiotherapy after breast-conserving surgery with a policy of targeted intraoperative radiotherapy (also known as TARGIT) to the tumour bed with additional whole breast radiotherapy in a subgroup of patients (around 15%) with poor features on fi nal pathology would not lead to inferior local control of breast cancer.
Methods

Study design and participants
TARGIT-A was a pragmatic, prospective, international, multicentre, randomised, phase 3 trial that compared targeted intraoperative radiotherapy with the conventional policy of whole breast external beam radiotherapy. An outline of the protocol and the full protocol are available online. Women with early breast cancer were eligible for enrolment if they were aged 45 years or older and were suitable for wide local excision for invasive ductal carcinoma that was unifocal on conventional examination and imaging (MRI was not necessary for confi rming unifocality). Preoperative diagnosis of lobular carcinoma was an exclusion criterion. Patients gave written informed consent to join the trial. The protocol was approved by the appropriate regulatory and ethics authorities for each centre before enrolment could begin. The initial trial plan was developed in University College London (UCL), London, UK. Management of the trial was coordinated and supervised by the international steering committee (ISC) with advice from the data monitoring committee (DMC). Representatives from the manufacturer of the Intrabeam equipment (Carl Zeiss, Oberkochen, Germany) attended the ISC meetings as observers. The trial statistician supervised all data analyses. The interpretation of the analyses, presentation of data at meetings, and preparation of manuscripts for publication are all responsibilities of the ISC. The TARGIT Trials Operations Offi ce is located at UCL and is responsible for randomisations, data collection, data management, and servicing of the ISC and DMC. No changes were made to the methods after commencement of the trial.
Before centres were allowed to participate, the team was trained and audited by a member of the ISC. Each centre was allowed to restrict the inclusion criteria beyond the core protocol, and to stipulate local policy for giving external beam radiotherapy (typically 40-56 Gy with or without a boost of 10-16 Gy, standard tangents, etc) both in the external beam radiotherapy group and as an additional dose in the targeted intraoperative radiotherapy group, in a site-specifi c treatment policy document that was reviewed and signed off by the ISC before randomisation could begin. 
Procedures
The concept and technique of targeted intraoperative radiotherapy, which was pioneered by our group, [17] [18] [19] is designed to allow the patient to receive all required radiation in a single fraction before she awakes from surgery. The clinicopathological rationale, the technology of the device, surgical technique (fi gure 1), radiobiology, and acute and long-term toxicity have been previously described. 5, [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] Briefl y, the Intrabeam device provides a point source of low energy x-rays (50 kV maximum) at the tip of a 3·2 mm diameter tube that is placed at the centre of a spherical tumour bed applicator. After surgically positioning the appropriately sized applicator in the tumour bed, radiation is switched on for 20-35 min to target the tissues that are at highest risk of local recurrence. The surface of the tumour bed typically receives 20 Gy that attenuates to 5-7 Gy at 1 cm depth. We established the safety and tolerability of the technique in phase 2 studies started in July, 1998, 17, 20 in which targeted intraoperative radiotherapy was delivered as a substitute for tumour bed boost, followed by standard external beam radiotherapy to the whole breast. The most recent update, in 300 patients, has a median follow-up of 60·5 months and the 5-year Kaplan-Meier estimate for ipsilateral recurrence was 1·74% (SE 0·77). 25 In this trial, we compared the conventional policy of whole breast external beam radiotherapy with the experimental policy of targeted intraoperative radiotherapy given in a single dose. We recognised that because of unfavourable features found subsequently in the pathological examination of the excised lesion (eg, lobular carcinoma), some patients (around 15%) assigned to targeted intraoperative radiotherapy will need to have external beam therapy in addition (without the boost that would already have been provided by the targeted intraoperative dose). (B) Postpathology entry/TARGIT as a second procedure. Postpathology entry allowed for patients randomised for entry to the trial only once the pathological characteristics of the tumour had been reported. If allocated to TARGIT the wound was opened, the applicator inserted, and TARGIT given as a second surgical procedure. *Decided by each centre at the outset-eg, grade 3, node involvement, lymphovascular invasion.
Randomisation and masking
The randomisation schedules were generated centrally by computer (securely kept in trial centres in Perth for Australian centres and London, UK, for all other centres). Requests for randomisation were via telephone or fax to the trials offi ce (Perth or London), where a trained member of staff checked patient eligibility. Treatment was allocated from a pre-printed randomisation schedule available to authorised staff only. Written confi rmation of randomisation was sent by fax to the site. Patients were randomly assigned in a 1:1 ratio to receive targeted intraoperative radiotherapy or external beam radiotherapy, with blocks stratifi ed by centre and by timing of delivery of targeted intraoperative radiotherapy. Three strata were used to stratify patients by timing of delivery. Details of the fi rst two strata (prepathology entry and postpathology entry/targeted intraoperative radiotherapy as a second procedure) are given in fi gure 2.
If a patient otherwise suitable for the TARGIT-A trial was found to have a history of previous contralateral breast cancer, we did not exclude them. Such patients were expected to be few and we wished to ensure that their distribution between the two groups remained balanced. Hence they were randomised in a third stratum.
Neither patients nor investigators or their teams were masked to treatment given after randomisation. Individual sites were unblinded to treatment given to their own patients, but they were not given access to these data for other sites. Confi dential unblinded reports for the DMC, and blinded reports for the ISC were produced by the trial statistician. Unblinded analyses were done according to a prespecifi ed statistical analysis plan.
Outcomes
Patients' assessments were scheduled at entry, 3 months, and 6 months; thereafter, they were scheduled every 6 months up to 5 years, and then yearly for up to 10 years.
The primary outcome of the trial was pathologically confi rmed local recurrence in the conserved breast. The secondary outcome measure of local toxicity or morbidity was assessed from data recorded on the complications form, which contained a prespecifi ed checklist: Centres are listed in the order that they joined the trial. The patients randomised from each country were: UK 469 (21%), Germany 571 (26%), Denmark 302 (14%), Australia 296 (13%), Italy 293 (13%), USA 207 (9%), Poland 41 (2%), Switzerland 40 (2%), Canada 13 (1%). haematoma, seroma, wound infection, skin breakdown, delayed wound healing, Radiation Therapy Oncology Group (RTOG version 2.0) toxicity grade 3 or 4 for dermatitis, telangiectasia, pain in irradiated fi eld, or other. We analysed seroma needing more than three aspirations, wound infections needing intravenous antibiotics, any complication needing surgical intervention, or (RTOG) toxicity grade more than 2. Skin breakdown or delayed wound healing or RTOG grade more than 2 were classifi ed as major toxicity.
To compare the extent of local surgery we analysed the specimen weight, margin status, and re-operation for margins. No changes were made to trial outcomes after commencement of the trial.
Statistical analysis
The predefi ned non-inferiority margin was an absolute diff erence of 2·5% in the primary endpoint between groups. To test for non-inferiority with a background 5-year recurrence rate of 6% 12, 26 and an absolute noninferiority margin of 2·5%, a total sample size of 2232 patients was calculated for 80% power at a 5% signifi cance level.
The analysis was done in accordance with the CONSORT guidelines. 27 Data lock was on May 2, 2010. All randomised patients were included in the intentionto-treat analysis, which compared the targeted intraoperative radiotherapy group with the external beam radiotherapy group, for effi cacy and safety of the strategy. For the analysis of local recurrence in the conserved breast, patients who underwent mastectomy as their defi nitive surgery (for reasons such as positive margins, patient choice, etc) and patients who died or withdrew consent for further follow-up were censored on that date. All other recurrences in the conserved breast, but not axilla, were analysed and Kaplan-Meier curves were plotted to account for time to event and censoring of the data and included all patients. We also analysed the annual hazards of local recurrence in the conserved breast. This trial is registered with ClinicalTrials.gov, number NCT00983684.
Role of the funding source
This was an academically driven trial. The funding bodies had no role in trial design, data analysis, data interpretation, or writing of the report. Carl Zeiss has partly supported a few centres for help in data collection. The corresponding author had full access to all data in the study. All authors had fi nal responsibility for the decision to submit for publication.
Results
The fi rst patient was randomised on March 24, 2000, and the trial recruited patients from 28 centres in nine countries. 1113 patients were randomly allocated to targeted intraoperative radiotherapy and 1119 were allocated to external beam radiotherapy. Table 1 shows the distribution of patients in individual sites and strata. Figure 3 shows the trial profi le. 89% of patients in the targeted intraoperative radiotherapy group and 92% in the external beam radiotherapy group received the allocated treatment. Of those who received the allocated treatment in the targeted intraoperative radio therapy group, 86% received targeted intraoperative radiotherapy only and 14% received targeted intra operative radiotherapy plus external beam radiotherapy (fi gure 3), matching the 15% expectation in the protocol.
Follow-up information was available for 1668 (99%) patients randomised before May 2, 2009, and 1945 (98%) patients randomised before Nov 2, 2009, 12 months and 6 months before the data lock, respectively. Table 2 shows patient and tumour characteristics. The median age was 63 years (IQR 57-69) and 1834 (82%) patients were younger than 70 years. Tumour sizes were small: 36% were less than 1 cm, 50% were between 1 cm and 2 cm, and 14% were more than 2 cm. Most tumours were grade 1 (34%) or 2 (50%); only 15% were grade 3. Nodes were uninvolved in 83% of patients. 66% of systemic therapy was hormonal and 12% was chemotherapy. Table 3 shows that the median amount of tissue excised during breast-conserving surgery was similar in the two groups, as was the proportion of fi rst excisions with free margins. The diff erence in re-excision rates was not signifi cant between the two main strata (prepathology 119 [7·8%] vs postpathology 63 [9·0%], p=0·31) or between the two groups (table 3; p=0·07).
The number of patients with any complication (table 4) was similar in the two groups. signifi cant complications, three of which were similar in the two groups. Wound seroma needing more than three aspirations were more frequent in the targeted intraoperative radiotherapy group than in the external beam radiotherapy group, whereas RTOG score of 3 or 4 was more frequent in the external beam radiotherapy group than in the targeted intraoperative radiotherapy group. The total rate of major toxicities was similar in the two groups. The number of axillary recurrences (targeted intraoperative radiotherapy, four vs external beam radiotherapy, three) and uncontrolled local recurrences at the time of death (one in each group) were similar in the two groups.
At 4 years, there were six local recurrences in the intraoperative radiotherapy group and fi ve in the external beam radiotherapy group. Figure 4 shows the results for the primary endpoint of local recurrence. Figure 4A is the Kaplan-Meier plot for the whole cohort and shows narrow 95% CIs. Figure 4B shows the two randomised groups. There was no signifi cant diff erence in the Kaplan-Meier estimate of local recurrence in the conserved breast between the targeted intraoperative radiotherapy and external beam radiotherapy groups at 4 years (1·20%, 95% CI 0·53-2·71 vs 0·95%, 0·39-2·31; diff erence between groups 0·25%, -1·04 to 1·54; logrank test, p=0·41). Figure 4C shows the annual hazard of local recurrence in the fi rst 4 years and the expected peak of recurrence in the second and third year with overlapping CIs for the targeted intraoperative radiotherapy and external beam radiotherapy groups.
Discussion
This large, international randomised trial provides robust and mature evidence that substantiates previous fi ndings showing that targeted intraoperative radiotherapy is safe. Rates of overall complications and major complications were similar in the targeted intraoperative radiotherapy and external beam radiotherapy groups. Although there was a higher risk of seroma needing aspiration in patients assigned to targeted intraoperative radiotherapy than in those assigned to conventional treatment, this event was more than compensated for by signifi cantly lower radiotherapy-related complications in the targeted intraoperative radiotherapy group (RTOG toxicity grade 3 or 4).
When the original sample size of 2232 was calculated, we based our estimate of 5-year local recurrence rate of 6% on the literature available in 1999. 12, 26 We chose the noninferiority margin as an absolute diff erence of 2·5% because this seemed clinically acceptable to physicians and patients. However, during the past decade recurrence rates have substantially reduced. The recurrence rate in the control group of our trial was 0·95% at 3 years. It would be logical to extrapolate the 5-year local recurrence rate to 1·5%, which is not unexpected. For example, in the UK Standardisation of Breast Radiotherapy (START) trial, 29 patients had a worse prognosis (eg, 36% had a tumour size of more than 2 cm vs 14% in TARGIT-A and 22% were node positive vs 17% in TARGIT-A) and were treated a few years before patients were in our trial. In the START trial, the recurrence rate at 5 years was 2·3%. Therefore the estimate of 1·5% for our trial is not unrealistic.
The absolute non-inferiority margin of 2·5% could still be deemed reasonable because a 2·5% diff erence in local recurrence at 5 years would translate into a 0·625% diff erence in mortality at 15 years (by use of the 4:1 ratio reported in the analysis by the Early Breast Cancer Trialists' Collaborative Group 30 ), a magnitude that could be considered acceptable. 31 In fact, two patient preference studies 32, 33 have suggested that the median additional increase that would be accepted in exchange for the convenience of a single treatment dose is 2·5%.
Thus, with a background recurrence rate at 5 years of only 1·5%, a trial for testing a non-inferiority margin of 2·5% with 80% power and 95% confi dence needs a sample size of only 585 (table 6) . 34 In our trial of 2232 patients, the number of patients with a median follow-up of 4 years was 862 and the number with a median follow-up of 3 years was 1514, well above the required 585 who already have a median follow-up of 4·5 years. Studies of temporal distribution of local recurrence suggest that this period covers the peak hazard of local recurrence that occurs between Data are number of patients (%). RTOG=Radiation Therapy Oncology Group. *Some of the patients in the fi rst three rows (haematoma needing surgical evacuation, seroma needing more than three aspirations, infection needing intravenous antibiotics or surgical intervention) could be included in the fourth row (skin breakdown or delayed wound healing). †No patient had grade 4 toxicity. ‡Defi ned as skin breakdown or delayed wound healing and RTOG toxicity grade of 3 or 4). 2-3 years after surgery, 35 thus it is arguable that our results do have the maturity of follow-up in large enough numbers to draw cautious yet reasonable conclusions about effi cacy.
The local recurrence rate in the targeted intraoperative radiotherapy group was not signifi cantly diff erent from that in the external beam radiotherapy group (1·2% vs 0·95%, p=0·41 at 4 years). As previously mentioned, the number of patients needed for testing a non-inferiority margin of 2·5% with 80% power and 95% confi dence (n=585) have indeed completed a median 4·5 years of follow-up (minimum 3·6 years). One could therefore conclude that the targeted intraoperative radiotherapy approach is non-inferior in terms of effi cacy to control local recurrence in selected patients covering the period at maximum hazard for such events. Our results have established a clinically relevant non-inferiority with a margin of 1·5%.
Furthermore, in the fourth year, with 739 patients at risk, there was no local recurrence in either group, suggesting that our results are robust. The results conform to the idea that the peak hazard of local recurrence has passed by year 4.
To cater for a wide level of equipoise, our design was pragmatic with restrictions for age (≥45 years) and tumour size (preferably smaller than 3·5 cm) kept to a minimum, and no restrictions for grade and nodal status. At the outset, each centre specifi ed these options in a treatment policy document. Allowing clinicians to be liberal in their intended inclusion criteria increased appeal and encouraged wider participation, yet led to a fairly homogeneous low risk patient sample, which showed an unsurprising conservatism among participating clinicians in this pragmatic trial. 36 Biologically, these results challenge two very diff erent dogma, fi rst that whole breast radiotherapy is necessary in this group of patients, and, second, that the traditional radiation dose (much higher than targeted intraoperative radiotherapy) is essential for eff ective tumour control.
Another interesting biological paradox is that the proportional risk reduction achieved by radiotherapy is the same whether the margins are positive, narrow, or wide, although the absolute reduction diff ers. Of the breast-conserving trials that have tested the eff ect of radiotherapy, patients in most trials, 30 including National Surgical Adjuvant Breast and Bowel Project (NSABP) B06, 37 underwent less extensive surgery than did patients in the Milan III trial. 38 The recurrence rate in the control group of the Milan III trial, in which the tumour dimensions were smaller and excision was substantially wider than in other trials, was low (8·8% vs 24-27% in other trials). Nevertheless, radiotherapy reduced the recurrence rate even further and at the same proportional rate as it did in other trials. If local recurrence were caused by residual disease only, then radiotherapy should have aff ected a much larger proportional reduction in those patients with positive margins or less extensive surgery; but radiotherapy is as eff ective in patients with negative margins, suggesting that this modality of treatment might have an eff ect on the tumour microenvironment as well. 5 The notion that some of the benefi t from radiotherapy could result from a favourable eff ect on the tumour microenvironment 5 has been substantiated by translational research during targeted intraoperative radiotherapy. 39 In this study, the wound fl uid collected in the 24 h after surgical-wide local excision of cancer stimulated breast cancer cell lines to proliferate, migrate, and invade into Matrigel (BD Biosciences, San Jose, CA, USA). By contrast, the fl uid obtained from wounds that had received targeted intraoperative radiotherapy did not stimulate cancer cells. 39 A delay in delivery of radiotherapy either because of long waiting lists or because chemotherapy is given fi rst, could jeopardise its eff ectiveness. 40 A recent large study 41 in 18 050 patients has shown that timeliness does make an important diff erence. If radiotherapy is delivered intraoperatively, it would avoid a temporal miss 42 and enable the shortest possible interval between surgical resection of the cancer and accurate delivery of radiotherapy.
Mathematical models of radiotherapy 43 suggest that a smaller number of well targeted doses of radiotherapy are probably more eff ective than fractionated radiotherapy, which accords with the results of the START trial. 29 Additionally, the dose fall-off with the Intrabeam treatment mimics the decreasing tumour cell density with increasing distance from the border of the macroscopic tumour. This dose distribution led to a novel target volume theory, the sphere of equivalence, for targeted intraoperative radiotherapy treatment. 24 The model suggests that within such a sphere of equivalence 24 around the intraoperative radiotherapy applicator, local control should be equivalent to that achieved by a course of fractionated radiotherapy. The benefi cial eff ect of targeted intraoperative radiotherapy on tumour microenvironment might enlarge such a sphere of equivalence. 44 Although the traditional doses of fractionated radiation are much higher than the dose given with targeted intraoperative radiotherapy, the radiobiology of single doses under these circumstances is interestingly diff erent. First, the radiation from Intrabeam (50 kV) has been shown to have an increased relative biological eff ectivity (RBE) of 1·5-2·0, so the biological dose is much higher than the physical dose. Also, this RBE paradoxically increases with depth so that the clinically relevant dose fall-off is less steep than is suggested from the mere physical dose distribution. 21, 24, 45, 46 Second, the intraoperative dose is given at the earliest possible time and within a short period. Therefore, there is no loss of dose because of tumour cell proliferation between surgery and the initiation of radiotherapy, and between the fractions of a fractionated course of radiotherapy. We previously reported 24 that within the limits of the currently available radiobiological models, the dose of 20 Gy at the applicator surface is equivalent to a fractionated dose of 70 Gy.
There are several other trials of partial breast irradiation that use various techniques, including the ELIOT, 47 NSABP-B39, GEC ESTRO, and Hungarian trials. 48 The ELIOT trial 47 is the only other trial that uses single fraction intraoperative radiotherapy and a mobile linear accelerator that generates electrons at various energy levels. While the radiotherapy with targeted intraoperative treatment is given from within the breast with minimum additional dissection of the breast, the ELIOT technique 47 requires the breast tissue to be dissected off the skin and the chest wall and brought together for irradiation from outside the breast. The other trials use well-established techniques such as radioactive interstitial implants, intensity modulated and three-dimensional conformal radiotherapy, and interstitial balloon devices. Like TARGIT-A, all these trials are aimed at testing the idea of partial breast irradiation as an alternative to whole breast irradiation.
The implications of our results for day-to-day clinical practice will be aff ected by emerging data from these trials, as well as the individual circumstances of the patient. Furthermore, we need longer term follow-up of our own trial to monitor the clinical appearance of new primary tumours outside the index quadrant or delayed recurrences inside the index quadrant. If the results of these trials refl ect our results then the range of techniques available will mean that clinicians and patients will have a choice and could make individualised decisions based on the evidence available for each technique, patient preference, local resources, and professional expertise. We wish to urge caution while applying these results to clinical practice; although targeted intraoperative radiotherapy provides eff ective local control in the period of peak hazard (fi rst 4 years), the results are valid only for patients with the clinicopathological features similar to those in this trial. In addition to the obvious benefi ts of completing all the necessary radiotherapy in a single session at the time of surgery, targeted intraoperative radiotherapy almost completely avoids irradiation of the intrathoracic structures such as the heart, lung, and oesophagus. 21 Consequently, the damage to these structures, which can occur even with modern external beam radiotherapy, 49 will have been avoided. We will monitor late cardiac toxicity in these patients to assess whether it is indeed lower in the targeted intraoperative radiotherapy group than in the external beam radiotherapy group.
A crucial issue in understanding this trial centres on the benefi ts to the patient and the eff ect on the workload of a radiotherapy centre. Treatment of patients with breast cancer accounts for about a third of the workload of radiotherapy departments in some parts of the world and contributes substantially to the unacceptable waiting lists seen in many oncology departments worldwide. In countries such as the UK where the waiting list for postoperative radiotherapy could rapidly diminish with use of targeted intraoperative radiotherapy, we estimate savings of around £15 000 000 (US$23 000 000) a year. 5 When making decisions about which operation to choose, the main factors women are concerned about are tumour recurrence, the need for radiation therapy, and speed of recovery. 50 Consequently, because the defi nitive treatment with radiation can be completed at the time of the surgery or shortly afterwards in a single session with targeted intraoperative radiotherapy, two of the patients' major concerns are immediately addressed, and perhaps fewer patients should feel obliged to choose mastectomy over breast-conserving surgery either because they live far away from a radiotherapy facility 51 or to avoid prolonging their treatment. Furthermore, since the risk of local recurrence with targeted intraoperative radiotherapy is similar to that with conventional external beam radiotherapy, then this approach should eff ectively deal with all three of the major concerns of women with breast cancer.
Our results bring us closer to a scenario in which a patient with early breast cancer might complete all her local treatment, surgical excision, sentinel lymph node biopsy, and radiotherapy at one or two visits, without having to stay overnight in a hospital bed. Together with the developments in adjuvant systemic therapy, these advances could substantially reduce the eff ect of a breast cancer diagnosis and treatment on a woman's life.
